| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 |
Form 4/A: Chernett Jorey, 10% owner
Acquired 1,391 Call Option (STLN 19FEB27 $4C) (Open Market Purchase) ($1.11K) |
| 13 Nov 2026 | 25-NSE |
| 12 Nov 2026 |
8-K/A: Regulation FD Disclosure
Some of the information in this presentation is not historical in nature and may constitute forward - looking statements, which ar e made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The... |
| 12 Nov 2026 |
Form 4: Chernett Jorey, 10% owner
Acquired 1,391 Call Option (STLN 19FEB27 $4C) (Open Market Purchase) ($1.11K) |
| 12 Nov 2026 |
8-K: Regulation FD Disclosure
Some of the information in this presentation is not historical in nature and may constitute forward - looking statements, which ar e made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The... |
| 10 Nov 2026 |
Form 4: Chernett Jorey, 10% owner
Sold 2,851,061 shares ($11.4M) · Acquired 10,000 Call Option (STLN 20NOV26 $4C) (Open Market Purchase) ($750) · Acquired 5,000 Call Option (STLN 19FEB27 $4C) (Open Market Purchase) ($2K) · 3 more |
| 06 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
CERRITOS, Calif., November 5, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended... |
| 02 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 1, 2026, Brad Hively notified Starling Oncology, Inc. (the “Company”) of his decision to not stand for re-election to the Board of the Directors of the Company (the “Board”) at its 2027 annual meeting of stockholders (the “A... |
| 24 Aug 2026 |
Form 4: Hively Brad, Director
Sold 298,853 shares ($1.95M) |
| 21 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
STARLING ONCOLOGY MANAGEMENT, LIMITED LIABILITY COMPANY f/k/a TOI MANAGEMENT, LLC |
| 21 Aug 2026 | 144 |
| 17 Aug 2026 |
Form 4: Chernett Jorey, 10% owner
Disposed of 100 Call Option (STLN 19FEB27 $9C) (Open Market Sale) ($624) · Bought 12,000 shares ($78.5K) |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
CERRITOS, Calif., August 6, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended J... |
| 03 Aug 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure
Company to begin trading on Nasdaq under new ticker symbol “STLN,” replacing “TOI” |
| 29 Jul 2026 |
Form 4: Kaushal Mohit, Director
Received 33,133 shares as a grant or award |
| 29 Jul 2026 |
Form 4: McGeorge Anne, Director
Received 41,165 shares as a grant or award |
| 29 Jul 2026 |
Form 4: Pacala Mark L, Director
Received 30,120 shares as a grant or award |
Loading...